VISTA: A promising target for overcoming immune evasion in gynecologic cancers.

IF 4.8 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2024-09-10 Epub Date: 2024-07-09 DOI:10.1016/j.intimp.2024.112655

Sicong Liu, Feng Ji, Yue Ding, Bo Ding, Songwei Feng, Cory Brennick, Hao Lin, Tianxiang Zhang, Yang Shen

引用次数: 0

Abstract

Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment but has shown limited efficacy in gynecologic cancers. VISTA (V-domain Ig suppressor of T-cell activation), a member of the B7 family, is emerging as another checkpoint that regulates the anti-tumor immune responses within the tumor microenvironment. This paper reviews the structure, expression, and mechanism of action of VISTA. Furthermore, it highlights recent advances in VISTA-blocking therapies and their potential in improving outcomes for patients with gynecologic cancers. By understanding the role of VISTA in mediating the immune evasion of gynecologic tumors, we can develop more effective combinatory treatment strategies that could overcome resistance to current ICB therapies.

查看原文本刊更多论文

VISTA：克服妇科癌症免疫逃避的有望靶点。

免疫检查点阻断（ICB）疗法为癌症治疗带来了革命性的变化，但对妇科癌症的疗效有限。B7家族成员VISTA（V-domain Ig suppressor of T-cell activation）正在成为另一种调节肿瘤微环境中抗肿瘤免疫反应的检查点。本文回顾了 VISTA 的结构、表达和作用机制。此外，本文还重点介绍了阻断 VISTA 疗法的最新进展及其改善妇科癌症患者预后的潜力。通过了解 VISTA 在介导妇科肿瘤免疫逃避中的作用，我们可以开发出更有效的联合治疗策略，从而克服目前 ICB 疗法的抗药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.